PS
IRWD icon

Principal Securities’s Ironwood Pharmaceuticals IRWD Stock Holding History

Principal Securities’s Portfolio IRWD Stock Details IRWD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-128
Closed -$168 – 2446
2025
Q3 		$168 Buy
+128
New +$132 ﹤0.01% 3661
2024
Q4 		– Sell
-134
Closed -$552 – 3584
2024
Q3 		$552 Sell
134
-54
-29% -$290 ﹤0.01% 3258
2024
Q2 		$1.23K Sell
188
-810
-81% -$5.73K ﹤0.01% 3022
2024
Q1 		$8.69K Sell
998
-157
-14% -$1.91K ﹤0.01% 2400
2023
Q4 		$13.2K Buy
+1,155
New +$11.4K ﹤0.01% 2120

Other funds holding IRWD

AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SCM
Sarissa Capital Management Greenwich, Connecticut $158M AUM 103.7% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Principal Securities's IRWD Position: Q4 2025 in Review

Principal Securities sold out of Ironwood Pharmaceuticals (IRWD) in Q4 2025, closing a stake of 128 shares — an estimated $168 sold.

Principal Securities first reported a position in IRWD in Q4 2023 and held it in 5 quarters. The position peaked at $13.2K in Q4 2023. 199 funds tracked by Wall St. Rank hold IRWD as of Q4 2025.

  • Principal Securities reported no remaining Ironwood Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
  • Principal Securities sold 128 Ironwood Pharmaceuticals shares in Q4 2025, an estimated $168.
  • Principal Securities first reported a position in Ironwood Pharmaceuticals in Q4 2023 and held it in 5 quarters.
  • Principal Securities's Ironwood Pharmaceuticals position peaked at $13.2K in Q4 2023.
  • 199 funds tracked by Wall St. Rank held Ironwood Pharmaceuticals as of Q4 2025.

Based on Principal Securities's 13F filing for Q4 2025, filed 12 Feb 2026.